Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, March 27, 2019
STA Pharmaceutical WuXi STA announces its new drug product manufacturing facility in Waigaoqiao Free Trade Zone of Shanghai has passed its first GMP inspection by the European MPA.
read more
Monday, December 09, 2019
WuXi Vaccines will invest 240 million USD and build a new vaccine manufacturing facility in Ireland.
read more
Wednesday, December 13, 2023
WuXi Vaccines was named Best Vaccine CMO of the Year for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony.
read more
WuXi Vaccines announced that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Practices (GMP) certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA).
read more
STA Pharmaceutical, a WuXi AppTec group company, has merged with WuXi AppTec’s Pharmaceutical Development Services division.
read more
Tuesday, December 05, 2023
X-Chem, a company specializing in drug discovery services, has proudly announced a significant milestone in drug discovery, marking the successful advancement of a development candidate by one of its partners.
read more
Monday, February 01, 2021
X-Chem has acquired IntelliSyn, a Montreal-based drug discovery services company and its US-based sister company, AviSyn.
read more
Wednesday, April 03, 2024
X-Chem, a provider of solutions for early-stage drug discovery, announced the addition of Dr. Erin Davis as chief technology officer.
read more
Tuesday, January 31, 2023
X-Chem, a provider of solutions for early-stage drug discovery, announced the expansion of its collaboration with Kymera Therapeutics, Inc. With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based ...
read more
X-Chem announced the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline.
read more
Wednesday, March 30, 2016
X-Chem, a privately held biotechnology company applying its DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, has announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical ...
read more
X-Chem, a provider of DNA-encoded library (DEL)-based discovery services, has announced the global launch of its OpenDEX solution.
read more
Thursday, August 10, 2023
X-Chem announced the addition of Karen Lackey as chief scientific officer (CSO) and David Hagerman as chief financial officer (CFO) to its global executive management team.
read more
Wednesday, January 06, 2016
X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, announced a multi-target collaboration with Sanofi.
read more
Wednesday, January 17, 2018
X-Chem announced an expansion of their existing global drug discovery collaboration with AstraZeneca.
read more